TY - JOUR
T1 - Impact of Post-progression Survival on Outcomes of Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma
T2 - A Systematic Review and Retrospective Cohort Study
AU - Tajiri, Kazuto
AU - Tokimitsu, Yoshiharu
AU - Kawai, Kengo
AU - Motofuji, Yuchi
AU - Shinno, Eiji
AU - Kashii, Yoshiro
AU - Muraishi, Nozomu
AU - Murayama, Aiko
AU - Hayashi, Yuka
AU - Minemura, Masami
AU - Takahara, Terumi
AU - Shimizu, Yukihiro
AU - Yasuda, Ichiro
N1 - Publisher Copyright:
© 2022 International Institute of Anticancer Research. All rights reserved.
PY - 2022/12
Y1 - 2022/12
N2 - Background/Aim: Lenvatinib is a tyrosine kinase inhibitor (TKI) more effective against hepatocellular carcinoma (HCC) than sorafenib, making lenvatinib a first-line treatment option for patients with unresectable HCC. In patients treated with sorafenib, post-progression survival (PPS) rather than progression-free survival (PFS) is essential for overall survival (OS). However, the importance of PPS for OS in patients treated with lenvatinib is uncertain, and optimal treatment after lenvatinib failure has not yet been established. Patients and Methods: The present study investigated the correlations of PFS and PPS with OS in studies of HCC patients treated with lenvatinib by weighted linear regression analysis. Furthermore, the contribution of treatment regimens after lenvatinib failure to OS were evaluated in daily clinical practice. Results: An analysis of 20 studies with 4,054 patients found that PPS had a stronger correlation with OS (r=0.869, p<0.001) than did PFS (r=0.505, p=0.007). Analysis of 79 patients with unresectable HCC treated with first-line lenvatinib showed that subsequent treatment was the most significant contributor to OS. Second-line sorafenib was administered to 25 patients, with late transition to third-line treatment being highest among patients who received second-line treatment. Conclusion: PPS contributes significantly to OS in HCC treatment with TKIs, with multi-sequential treatment being a key determinant of longer OS.
AB - Background/Aim: Lenvatinib is a tyrosine kinase inhibitor (TKI) more effective against hepatocellular carcinoma (HCC) than sorafenib, making lenvatinib a first-line treatment option for patients with unresectable HCC. In patients treated with sorafenib, post-progression survival (PPS) rather than progression-free survival (PFS) is essential for overall survival (OS). However, the importance of PPS for OS in patients treated with lenvatinib is uncertain, and optimal treatment after lenvatinib failure has not yet been established. Patients and Methods: The present study investigated the correlations of PFS and PPS with OS in studies of HCC patients treated with lenvatinib by weighted linear regression analysis. Furthermore, the contribution of treatment regimens after lenvatinib failure to OS were evaluated in daily clinical practice. Results: An analysis of 20 studies with 4,054 patients found that PPS had a stronger correlation with OS (r=0.869, p<0.001) than did PFS (r=0.505, p=0.007). Analysis of 79 patients with unresectable HCC treated with first-line lenvatinib showed that subsequent treatment was the most significant contributor to OS. Second-line sorafenib was administered to 25 patients, with late transition to third-line treatment being highest among patients who received second-line treatment. Conclusion: PPS contributes significantly to OS in HCC treatment with TKIs, with multi-sequential treatment being a key determinant of longer OS.
KW - Hepatocellular carcinoma
KW - lenvatinib
KW - post-progression survival
KW - sequential therapy
KW - sorafenib
KW - tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=85143182283&partnerID=8YFLogxK
U2 - 10.21873/anticanres.16112
DO - 10.21873/anticanres.16112
M3 - 学術論文
C2 - 36456142
AN - SCOPUS:85143182283
SN - 0250-7005
VL - 42
SP - 6007
EP - 6018
JO - Anticancer Research
JF - Anticancer Research
IS - 12
ER -